ArticleHaematologica2009
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.
Article in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 63 citations in OpenAlex.
- Myc rearrangement redefines the stratification of high-risk multiple myeloma.Cancer medicine · 2024Article
- Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.Cell communication and signaling : CCS · 2022Article
- The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.Exploration of targeted anti-tumor therapy · 2021Review
- Article
- A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.Haematologica · 2018Article
- The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.Haematologica · 2017Article
- RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.British journal of haematology · 2017Article
- Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Mayo Clinic proceedings · 2017Review
- Article
- The road to cure in multiple myeloma starts with smoldering disease.Expert opinion on orphan drugs · 2015Article
- Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.Leukemia & lymphoma · 2015Article
- How I treat smoldering multiple myeloma.Blood · 2014Article
- Early lymphoid lesions: conceptual, diagnostic and clinical challenges.Haematologica · 2014Review
- Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.Leukemia · 2014Article
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.Leukemia · 2014Article
- Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.Leukemia · 2012Article
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.Leukemia · 2011Article
- Review
- Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.Clinical lymphoma, myeloma & leukemia · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report serial genetic studies on a young female patient initially diagnosed with asymptomatic smouldering myeloma who progressed to symptomatic myeloma 4.5 years after presentation. An unbalanced translocation, der(14)t(4;14)(p16;q32), was initially found in all plasma cells plus deletions of other chromosomal regions as detected by array-based comparative genomic hybridization. Deletion of chromosome 13 was observed in a minor population of plasma cells (<20%) for the first two years, increasing to 100% of plasma cells by the time of multiple myeloma diagnosis. Loss of 1p and a rearrangement of MYC were first observed in a small population of plasma cells one year prior to the clinical diagnosis of multiple myeloma, but these subclones increased rapidly in size to become the major population suggesting that they were directly involved in the transformation process. This case report provides a unique insight into the mechanisms of disease progression from smouldering multiple myeloma to multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.